Do analysts prefer BCLI or SBFM?

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 2,904.29%. Given Sunshine Biopharma's higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer BCLI or SBFM?

In the previous week, Sunshine Biopharma had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Sunshine Biopharma and 3 mentions for Brainstorm Cell Therapeutics. Sunshine Biopharma's average media sentiment score of 0.27 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SBFM or NKGN?

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media favor ATON or SBFM?

In the previous week, Sunshine Biopharma had 5 more articles in the media than Portage Biotech. MarketBeat recorded 6 mentions for Sunshine Biopharma and 1 mentions for Portage Biotech. Sunshine Biopharma's average media sentiment score of 0.27 beat Portage Biotech's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Portage Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sunshine Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SBFM or SYBX?

Sunshine Biopharma presently has a consensus price target of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Sunshine Biopharma is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SBFM or SYBX?

In the previous week, Sunshine Biopharma had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Sunshine Biopharma and 1 mentions for Synlogic. Sunshine Biopharma's average media sentiment score of 0.27 beat Synlogic's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sunshine Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synlogic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate GRTX or SBFM?

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Galera Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sunshine Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Sunshine Biopharma (SBFM) Competitors

$2.33 -0.21 (-8.30%)

As of 01:48 PM Eastern

Compare

SBFM vs. BCLI, NKGN, ATON, SYBX, and GRTX

Should you buy Sunshine Biopharma stock or one of its competitors? MarketBeat compares Sunshine Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sunshine Biopharma include Brainstorm Cell Therapeutics (BCLI), NKGen Biotech (NKGN), Portage Biotech (ATON), Synlogic (SYBX), and Galera Therapeutics (GRTX). These companies are all part of the "pharmaceutical products" industry.

How does Sunshine Biopharma compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

Sunshine Biopharma has higher revenue and earnings than Brainstorm Cell Therapeutics. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Sunshine Biopharma	$36.31M	0.32	-$5.97M	-$1.29	N/A

In the previous week, Sunshine Biopharma had 3 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 6 mentions for Sunshine Biopharma and 3 mentions for Brainstorm Cell Therapeutics. Sunshine Biopharma's average media sentiment score of 0.27 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Brainstorm Cell Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Sunshine Biopharma has a consensus price target of $70.00, indicating a potential upside of 2,904.29%. Given Sunshine Biopharma's higher probable upside, analysts clearly believe Sunshine Biopharma is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats Brainstorm Cell Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Sunshine Biopharma compare to NKGen Biotech?

Sunshine Biopharma (NASDAQ:SBFM) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.0% of Sunshine Biopharma shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sunshine Biopharma currently has a consensus price target of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

NKGen Biotech has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. NKGen Biotech's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
NKGen Biotech	N/A	N/A	-479.36%

Sunshine Biopharma has higher revenue and earnings than NKGen Biotech. Sunshine Biopharma is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.32	-$5.97M	-$1.29	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.51	N/A

Sunshine Biopharma has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

In the previous week, Sunshine Biopharma had 6 more articles in the media than NKGen Biotech. MarketBeat recorded 6 mentions for Sunshine Biopharma and 0 mentions for NKGen Biotech. Sunshine Biopharma's average media sentiment score of 0.27 beat NKGen Biotech's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sunshine Biopharma	Neutral
NKGen Biotech	Neutral

Summary

Sunshine Biopharma beats NKGen Biotech on 10 of the 15 factors compared between the two stocks.

How does Sunshine Biopharma compare to Portage Biotech?

Portage Biotech (NASDAQ:ATON) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Portage Biotech has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

Portage Biotech has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Portage Biotech's return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	N/A	N/A
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

In the previous week, Sunshine Biopharma had 5 more articles in the media than Portage Biotech. MarketBeat recorded 6 mentions for Sunshine Biopharma and 1 mentions for Portage Biotech. Sunshine Biopharma's average media sentiment score of 0.27 beat Portage Biotech's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sunshine Biopharma has higher revenue and earnings than Portage Biotech. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$6.77M	-$8.18	N/A
Sunshine Biopharma	$36.31M	0.32	-$5.97M	-$1.29	N/A

13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 0.0% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Portage Biotech presently has a consensus price target of $2.00, suggesting a potential upside of 502.41%. Sunshine Biopharma has a consensus price target of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's higher possible upside, analysts clearly believe Sunshine Biopharma is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Sunshine Biopharma beats Portage Biotech on 9 of the 13 factors compared between the two stocks.

How does Sunshine Biopharma compare to Synlogic?

Sunshine Biopharma (NASDAQ:SBFM) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Sunshine Biopharma presently has a consensus price target of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Sunshine Biopharma is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sunshine Biopharma has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sunshine Biopharma	$36.31M	0.32	-$5.97M	-$1.29	N/A
Synlogic	$8K	1,008.87	-$23.36M	-$0.06	N/A

Synlogic has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Synlogic's return on equity of -26.47% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sunshine Biopharma	-18.45%	-27.75%	-21.57%
Synlogic	N/A	-26.47%	-18.00%

42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 0.0% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 2.6% of Synlogic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Sunshine Biopharma had 5 more articles in the media than Synlogic. MarketBeat recorded 6 mentions for Sunshine Biopharma and 1 mentions for Synlogic. Sunshine Biopharma's average media sentiment score of 0.27 beat Synlogic's score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synlogic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sunshine Biopharma beats Synlogic on 9 of the 16 factors compared between the two stocks.

How does Sunshine Biopharma compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Galera Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Sunshine Biopharma has higher revenue and earnings than Galera Therapeutics. Sunshine Biopharma is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.16
Sunshine Biopharma	$36.31M	0.32	-$5.97M	-$1.29	N/A

50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Galera Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.45%. Galera Therapeutics' return on equity of 0.00% beat Sunshine Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

Sunshine Biopharma has a consensus target price of $70.00, suggesting a potential upside of 2,904.29%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Galera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sunshine Biopharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sunshine Biopharma had 6 more articles in the media than Galera Therapeutics. MarketBeat recorded 6 mentions for Sunshine Biopharma and 0 mentions for Galera Therapeutics. Sunshine Biopharma's average media sentiment score of 0.27 beat Galera Therapeutics' score of 0.00 indicating that Sunshine Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Sunshine Biopharma	Neutral

Summary

Sunshine Biopharma beats Galera Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Sunshine Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBFM vs. The Competition

Export

Metric	Sunshine Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.67M	$3.32B	$6.30B	$12.61B
Dividend Yield	N/A	2.28%	2.68%	5.31%
P/E Ratio	-1.81	18.14	21.14	26.66
Price / Sales	0.32	331.61	548.71	114.72
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	0.50	6.87	9.92	6.91
Net Income	-$5.97M	$24.15M	$3.56B	$336.84M
7 Day Performance	-51.59%	2.78%	2.22%	3.97%
1 Month Performance	N/A	N/A	N/A	-0.58%
1 Year Performance	-83.48%	64.47%	36.80%	40.17%

Sunshine Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBFM Sunshine Biopharma	2.3889 of 5 stars	$2.33 -8.3%	$70.00 +2,904.3%	-82.0%	$11.67M	$36.31M	N/A	3	Short Interest Increase
BCLI Brainstorm Cell Therapeutics	0.1023 of 5 stars	$0.71 flat	N/A	-34.8%	$7.88M	N/A	N/A	40	Gap Down
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-79.2%	$7.84M	N/A	N/A	N/A
ATON Portage Biotech	1.0529 of 5 stars	$0.33 +3.8%	$2.00 +502.4%	N/A	$7.78M	N/A	N/A	6	Gap Up High Trading Volume
SYBX Synlogic	0.1017 of 5 stars	$0.66 flat	N/A	-41.9%	$7.72M	$8K	N/A	80	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBFM) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sunshine Biopharma (SBFM) Competitors

SBFM vs. BCLI, NKGN, ATON, SYBX, and GRTX

How does Sunshine Biopharma compare to Brainstorm Cell Therapeutics?

Summary

How does Sunshine Biopharma compare to NKGen Biotech?

Summary

How does Sunshine Biopharma compare to Portage Biotech?

Summary

How does Sunshine Biopharma compare to Synlogic?

Summary

How does Sunshine Biopharma compare to Galera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sunshine Biopharma (SBFM) Competitors

SBFM vs. BCLI, NKGN, ATON, SYBX, and GRTX

How does Sunshine Biopharma compare to Brainstorm Cell Therapeutics?

Is BCLI or SBFM more profitable?

Which has better earnings & valuation, BCLI or SBFM?

Does the media prefer BCLI or SBFM?

Do institutionals and insiders believe in BCLI or SBFM?

Which has more volatility and risk, BCLI or SBFM?

Do analysts prefer BCLI or SBFM?

Summary

How does Sunshine Biopharma compare to NKGen Biotech?

Do insiders and institutionals hold more shares of SBFM or NKGN?

Do analysts prefer SBFM or NKGN?

Is SBFM or NKGN more profitable?

Which has better earnings & valuation, SBFM or NKGN?

Which has more volatility & risk, SBFM or NKGN?

Does the media refer more to SBFM or NKGN?

Summary

How does Sunshine Biopharma compare to Portage Biotech?

Which has more risk & volatility, ATON or SBFM?

Is ATON or SBFM more profitable?

Does the media favor ATON or SBFM?

Which has better earnings and valuation, ATON or SBFM?

Do insiders and institutionals have more ownership in ATON or SBFM?

Do analysts prefer ATON or SBFM?

Summary

How does Sunshine Biopharma compare to Synlogic?

Do analysts rate SBFM or SYBX?

Which has more volatility and risk, SBFM or SYBX?

Which has stronger earnings & valuation, SBFM or SYBX?

Is SBFM or SYBX more profitable?

Do institutionals and insiders hold more shares of SBFM or SYBX?

Does the media favor SBFM or SYBX?

Summary

How does Sunshine Biopharma compare to Galera Therapeutics?

Which has more risk & volatility, GRTX or SBFM?

Which has preferable valuation & earnings, GRTX or SBFM?

Do institutionals & insiders have more ownership in GRTX or SBFM?

Is GRTX or SBFM more profitable?

Do analysts rate GRTX or SBFM?

Does the media prefer GRTX or SBFM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBFM vs. The Competition

Sunshine Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools